Table of Contents Large accelerated filer ☐ Accelerated filer ☒ Non-accelerated filer ☐ Smaller reporting company ☒ Emerging growth company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECT ...

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND THIRD QUARTER 2024 FINANCIAL RESULTS th Announced clear regulatory pathway to Accelerated Approval from U.S. Food and Drug Administration (FDA) for isaralgagene civaparvovec in Fabry disease, using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years. Pfizer plans to present detailed data from Phase 3 AFFINE t ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has been able to make several great advancements regarding its pipeline in the past year. The most notable program advancement would be regarding the fact that the company caught a huge surprise development from the FDA relating to its Fabry Disease treatment program. That is, it was noted by the U.S. agency that it would be able to file a Biologics License Application [BLA] of isaralgagene civaparvovec for the treatment of patients with Fabry Disease [FD] under an A ...

Experience: Former Fund Manager of a Hedge Fund focused on Biotech and Pharmaceutical companies. Over 20 years in the BioPharma Industry, including various roles on the commercial side. Investing Goal: Outperform the XBI each year by identifying and then investing in assets that should change the current standard of care in a particular disease. Portfolio sizing: Typically, high risk/high reward plays will be acquired up to 2 percent positions in my portfolio. More moderate risk/moderate reward positions ma ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Amy Pooler - Head of Research Nathalie Dubois-Stringfellow - Chief Development Officer Conference Call Participants Nicole Germino - Truist Securities Gena Wang - Barclays Yanan Zhu - Wells Fargo Maury Raycroft - Jefferies Lisa Walter - RBC Operator Good afternoon, and we ...

Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -6.25%. A quarter ago, it was expected that this drug developer would post a loss of $0.22 per share when it actually produced a loss of $0.27, delivering a surprise of -22.73%. Over the last four quarters, the compa ...

Table of Contents Large accelerated filer ☐ Accelerated filer ☒ Non-accelerated filer ☐ Smaller reporting company ☒ Emerging growth company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 1 ...

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2024 FINANCIAL RESULTS • Announced global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases. Expect to receive $50 million in near-term upfront license fees and milestone payments and eligible to earn up to $1.9 billion in milestone payments, plus tiered royalties on net sales. • Reported Pfizer's announcement of positive topline r ...

Sangamo Therapeutics (NASDAQ:SGMO) stock is rising higher on Tuesday after the clinical-stage genomic medicine company announced a new license agreement. Sangamo Therapeutics has signed a license agreement Genentech for the development of intravenously administered genomic medicines to treat "certain neurodegenerative diseases." That includes the company's proprietary zinc finger repressors for Alzheimer's disease. This agreement will see Sangamo handle technology transfer and some preclinical activities. G ...

SGMO 12 month stock chart on 07/22/24 (Seeking Alpha) Discussion on Financials Isa-vec is a GTx designed to carry the DNA for human alpha-Gal A to the liver of Fabry patients by a single IV infusion so that the liver can start producing functional alpha-Gal-A. The ph1/2 STAAR clinical trial (NCT04046224) dosed 24 patients who were either on ERT, been off it for 6 months or more, or were ERT-naïve. Dr. Robert Hopkin of Cincinnati Children's Hospital Medical Center was one of the investigators in the trial an ...